Global Information
회사소개 | 문의 | 비교리스트

인터류킨 15(IL15) : 파이프라인 리뷰

Interleukin 15 (IL15) - Pipeline Review, H2 2016

리서치사 Global Markets Direct
발행일 2016년 12월 상품 코드 365734
페이지 정보 영문 45 Pages
가격
US $ 3,500 ₩ 4,230,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 7,000 ₩ 8,460,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 10,500 ₩ 12,690,000 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


인터류킨 15(IL15) : 파이프라인 리뷰 Interleukin 15 (IL15) - Pipeline Review, H2 2016
발행일 : 2016년 12월 페이지 정보 : 영문 45 Pages

인터류킨(IL15)을 표적으로 한 치료제 개발 파이프라인 현황과 최신 업데이트에 의한 각 개발 단계 비교 분석, 기업과 연구기관이 개발중인 치료제, 치료제 평가, 후기 단계 및 중지된 프로젝트 관련 정보, 최신 뉴스와 발표 등을 전해드립니다.

1. 서론

  • 조사 범위

2. 인터류킨(IL15) 개요

3. 치료제 개발

  • 개발중인 제품 : 개발 단계별
  • 개발중인 제품 : 치료 영역별
  • 개발중인 제품 : 증상별

4. 파이프라인 제품 상황 개요

  • 후기 단계 제품
  • 초기 단계 제품

5. 기업에서 개발중인 제품

6. 대학/연구기관에서 개발중인 제품

7. 치료제 평가

  • 단일요법 제품/복합제별
  • 작용기전별
  • 투여 경로별
  • 분자 종류별

8. 치료제 개발에 참여하고 있는 기업

  • Amgen Inc.
  • Calypso Biotech SA
  • Digna Biotech, S.L.

9. 약제 개요

10. 휴지 상태인 프로젝트

11. 개발이 중지된 제품

12. 주요 뉴스 및 프레스 릴리스

13. 부록

14. 도표

LSH 16.08.22

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

Summary

Global Markets Direct's, 'Interleukin 15 (IL15) - Pipeline Review, H2 2016', provides in depth analysis on Interleukin 15 (IL15) targeted pipeline therapeutics.

The report provides comprehensive information on the Interleukin 15 (IL15) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Interleukin 15 (IL15) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Interleukin 15 (IL15)
  • The report reviews Interleukin 15 (IL15) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Interleukin 15 (IL15) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Interleukin 15 (IL15) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Interleukin 15 (IL15) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Interleukin 15 (IL15)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Interleukin 15 (IL15) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Interleukin 15 (IL15) Overview
  • Therapeutics Development
    • Interleukin 15 (IL15) - Products under Development by Stage of Development
    • Interleukin 15 (IL15) - Products under Development by Therapy Area
    • Interleukin 15 (IL15) - Products under Development by Indication
  • Interleukin 15 (IL15) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Interleukin 15 (IL15) - Products under Development by Companies
  • Interleukin 15 (IL15) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Interleukin 15 (IL15) - Companies Involved in Therapeutics Development
    • Amgen Inc
    • ARMO Biosciences Inc
    • Calypso Biotech SA
    • Novartis AG
    • ZIOPHARM Oncology Inc
  • Interleukin 15 (IL15) - Drug Profiles
    • AM-0015 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AMG-714 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ASN-006 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BNZ-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BNZ-2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CALY-002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cellular Immunotherapy for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NIZ-985 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Interleukin 15 (IL15) - Dormant Projects
  • Interleukin 15 (IL15) - Discontinued Products
  • Interleukin 15 (IL15) - Featured News & Press Releases
    • May 05, 2016: Celimmune Commences First-Ever Dosing with AMG 714 in Celiac Disease
    • Mar 31, 2016: Celimmune Commences Screening in Phase 2 Clinical Study in Refractory Celiac Disease Type II
    • Sep 23, 2015: Celimmune to Present Overview of Non-Dietary Celiac Disease Therapies in Development at Annual Celiac Support Association Meeting
    • Jun 22, 2015: Celimmune to Present Experimental Anti3IL315 Antibody AMG!714 at 16th International Coeliac Disease Symposium
    • Jun 18, 2015: Admune Announces the First-in-Human Study of Heterodimeric IL-15 with Broad Applications for Cancer Immunotherapy
    • Dec 15, 2006: Genmab Announces AMG 714 Development Update
    • May 16, 2006: AMG 714 Data To Be Presented At Eular Conference
    • Mar 10, 2006: Genmab Announces Update On AMG 714 Program With Amgen
    • Mar 23, 2004: Amgen Announces Positive Humax-IL15 Interim Phase II Data
    • Jan 23, 2003: Genmab A/S Announces FDA Approval To Initiate Phase II Clinical Study Using HuMax-IL15
    • Sep 04, 2002: Genmab Announces Positive Results From Phase I/II Clinical Trial Of HuMax-IL15 For The Treatment Of Rheumatoid Arthritis
    • Jul 01, 2002: Genmab Announces The Human Antibody Therapeutic Drug HuMax-IL15 Effectively Treats Psoriasis
    • Oct 03, 2001: Genmab Initiates Phase I/II Clinical Trial With HuMax-IL15 For The Treatment Of Patients With Rheumatoid Arthritis
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Indication, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Pipeline by Amgen Inc, H2 2016
  • Pipeline by ARMO Biosciences Inc, H2 2016
  • Pipeline by Calypso Biotech SA, H2 2016
  • Pipeline by Novartis AG, H2 2016
  • Pipeline by ZIOPHARM Oncology Inc, H2 2016
  • Dormant Projects, H2 2016
  • Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Top 10 Indication, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
Back to Top
전화 문의
F A Q